Clinical trials: sponsored by University of Oxford
Pre-eclampsia
Oxford Luteal Dysfunction and Placental Insufficiency Study
High blood pressure (BP) affects approximately 1 in 10 pregnancies. About half of women with high blood pressure in pregnancy develop a serious complication called preeclampsia, which kills over 70,000 women and 500,000 babies…
- Trial name
- OxLuPIn (NCT07072052)
- Testing
- No intervention planned
- Where
- United Kingdom
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Spinal Muscular Atrophy (SMA)
Service Evaluation for Newborn Screening for Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is a disease that causes progressive muscle weakness. There are many types- the most severe and most common, type 1, affects very young babies, and is life-threatening if untreated.
- Trial name
- SENS (NCT07888868)
- Where
- 3 sites in United Kingdom
- Volunteers
- 750,000 people
- Sponsor
- University of Oxford
Malaria,Falciparum
A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in infants aged 5-17 months in Burkina Faso
- Trial name
- NCT05790889
- Testing
- Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and…
- Trial name
- VAC093 (NCT06958198)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months…
- Trial name
- VAC087 (NCT07183371)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria
Southeast Asia Dose Optimization of Tafenoquine
Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the…
- Trial name
- SEADOT (NCT04704999)
- Testing
- Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg
- Where
- 6 sites in Cambodia, Indonesia and 3 more
- Volunteers
- 820 people
- Sponsor
- University of Oxford
Psychosis, First Episode Psychosis
Stratification and Treatment in Early Psychosis Study - ENHANCE
The purpose of this study is: To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of…
- Conditions
- Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
- Trial name
- STEP-ENHANCE (NCT06778564)
- Testing
- CBD 100 mg/mL Oral Solution
- Where
- 17 sites in Austria, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Treatment Resistant Psychosis, Psychosis
Stratification and Treatment in Early Psychosis Study -ASSIST
The purpose of this trial is: To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients.
- Trial name
- STEP-ASSIST (NCT07326124)
- Testing
- CBD 100 mg/mL Oral Solution, Placeb
- Where
- 15 sites in Germany, Greece and 6 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis
Stratification and Treatment in Early Psychosis Study - PROMOTE
The purpose of this trial is: To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
- Conditions
- Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
- Trial name
- STEP-PROMOTE (NCT07434973)
- Testing
- Cannabidiol (CBD)
- Where
- 19 sites in Austria, Canada and 8 more
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Febrile Illness
Incidences, Causes, and Outcomes of Febrile Illness in Rural South and Southeast Asia
The study will collect information to understand the causes and outcomes of febrile illness in rural areas in countries across South and Southeast Asia (including Cambodia, Laos, Myanmar and Bangladesh).
- Trial name
- SEACTN-WP-A (NCT04478578)
- Where
- 7 sites in Bangladesh, Burma and 3 more
- Volunteers
- 82,760 people
- Sponsor
- University of Oxford
Sepsis
Use of Procalcitonin, a Blood Test to Guide Antibiotic Therapy for Sepsis in Adults
Trial design: Randomised controlled, two-arm, parallel, clinical trial to assess the efficacy and safety of sequential daily procalcitonin assessments to guide de-escalation of empirical antibiotic therapy in adult patients with…
- Trial name
- PROCALBAN (NCT05955612)
- Testing
- Procalcitonin measurement
- Where
- Bangladesh
- Volunteers
- 532 people
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria, Vivax Malaria
Tafenoquine Drug Levels in Small Children
This study is an open label, single arm, pharmacokinetic trial. A total of 20 participants (children ≤12kg and >28 days old) will be enrolled.
- Trial name
- TQP (NCT07835321)
- Testing
- Chloroquine, Tafenoquine
- Where
- 2 sites in Thailand, Vietnam
- Volunteers
- 20 people
- Sponsor
- University of Oxford
Spinal Muscular Atrophy
Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).
The goal of this study is to investigate the acceptability, feasibility, safety and efficacy of an optimized rehabilitation program for treated patients with spinal muscular atrophy (SMA) compared to the current rehabilitation…
- Trial name
- ACE SMA (NCT06419322)
- Testing
- Optimized rehabilitation program
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- University of Oxford
Spinal Muscular Atrophy (SMA)
VRehab-SMA Phase 1.2
Spinal muscular atrophy is a genetic disorder characterized by progressive muscle weakness, severely impacting patients' motor abilities.
- Trial name
- NCT07578454
- Testing
- VRehab SMA device
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Preterm Birth
Molecular Signature Children
Preterm birth (PTB) occurs before 37 weeks of gestation and is a major cause of neonatal mortality and morbidity. PTB results from heterogeneous influences.
- Trial name
- MSP_Ext (NCT03104673)
- Where
- Thailand
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria (Plasmodium Falciparum)
Dose Finding Trial of R21/Matrix-M in School Children
This trial is a double-blind, randomised, trial recruiting participants from the R21 phase IIb trial (VAC 076) which took place between May 2019 and July 2023 in Nanoro, Burkina Faso.
- Trial name
- NCT07074665
- Testing
- 5µg R21/50µg Matrix-M, 10µg R21/50µg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Drug Resistance, Bacterial
Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand
The main goal of this retrospective observational study is to understand how stepping down antibiotic treatment (called antibiotic de-escalation) affects patients who receive it compared to those who don't after received a…
- Conditions
- Drug Resistance, Bacterial, Bacteremia
- Trial name
- NCT07082465
- Where
- 4 sites in Thailand
- Volunteers
- 108,000 people
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria, Malaria
R21/MM Dosing, Presentations, and Preservatives
This is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in children and adults.
- Conditions
- Plasmodium Falciparum Malaria, Malaria, Vaccine Reaction
- Trial name
- VAC100 (NCT07194668)
- Testing
- 10μg R21/50μg Matrix-M, 5μg R21/50μg Matrix-M with adaptor preservative free, 5μg R21/50μg Matrix-M with 2PE preservative
- Where
- 2 sites in Bangladesh
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Bacteremia
Surveillance of AMR in DRC
This study addresses knowledge gaps regarding antimicrobial resistance (AMR) in sub-Saharan Africa, focusing on evaluating the feasibility of AMR surveillance and enhancing local research capacity.
- Trial name
- SARKIN (NCT06821282)
- Where
- Democratic Republic of the Congo
- Volunteers
- 210 people
- Sponsor
- University of Oxford
Duchenne Muscular Dystrophy (DMD)
A Remote Study Using Technology to Assess Outcomes in DMD
Every year, 100 boys are born in the UK with a rare muscle disease called Duchenne muscular dystrophy. These boys cannot make an important muscle protein called dystrophin.
- Trial name
- TODDLER (NCT07423026)
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Oxford